<DOC>
	<DOCNO>NCT02305147</DOCNO>
	<brief_summary>Observational , prospective , monocentric study assess clinical feature , image biologic biomarkers Parkinson disease ( PD ) patient rate progression compare healthy control ( HC ) subject risk develop PD . The primary objective study identify clinical , image biologic marker PD onset progression use clinical trial disease-modifying therapy .</brief_summary>
	<brief_title>Cohort Study Identify Predictor Factors Onset Progression Parkinson 's Disease</brief_title>
	<detailed_description>ICEBERG four-year natural history study de novo idiopathic PD patient , healthy control , subject risk develop PD ( idiopathic Rem Behavior Disorder -iRBD , probants patient PD genetically confirm ) . All subject comprehensively assess baseline every year thereafter . Subjects undergo clinical ( motor , neuropsychiatric , sleep , ocular cognitive evaluation ) image assessment . Blood ( include DNA sample ) , stool , skin biopsy cerebral spinal fluid ( CSF ) sample collect .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>All subject : Male female age 18 year old , MMSE score &gt; 26 , negative pregnancy test potentially childbearing woman ( contraindication SPECT DatScan ) . Parkinson disease subject : diagnosis confirm accord UK Parkinson 's Disease Society Brain Bank criterion ( UKPDSBB ) ; disease duration le 3 year . Prodromal subject : subject identify relative PD genetically confirm subject diagnosis idiopathic Rem sleep Behavior Disorder ( iRBD ) ; neurological examination normal ( sign parkinsonism ) . Healthy subject : neurological examination normal All subject : Psychiatric disorder progressive lifethreatening disease , impairment preclude appropriate information instruction give concern participation study ; contraindication MRI SPECT scan . Parkinson disease subject : dopamine transporter deficit SPECT scan ; parkinsonism induce neuroleptic ; neuroleptic intake within 6 month ; atypical parkinson syndrom ( MSA , PSP , CBD ... )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Prognostic factor</keyword>
	<keyword>Prodromal feature</keyword>
	<keyword>Disease progression</keyword>
</DOC>